UPLIFT reassures some over Spiriva CV safety
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim/Pfizer's leading COPD treatment Spiriva (tiotropium bromide) failed to reduce the rate of decline in FEV
You may also be interested in...
GSK’s Dostarlimab Gets EU Nod For Endometrial Cancer
While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing in the EU for endometrial cancer.
COVID-19 Promise Fulfilled, But Where Next For mRNA Vaccines?
After a baptism of fire during the coronavirus pandemic, mRNA vaccine technology has earned its stripes. In less than a year, mRNA vaccines have been catapulted from interesting pipeline prospects to game-changers in the fight against COVID-19. But what does this success mean for the future of the technology?
AstraZeneca’s Imfinzi Fails Again In Head And Neck Cancer
The Phase III KESTREL study evaluating Imfinzi missed its primary overall survival benefit and a key secondary outcome in first-line recurrent or metastatic head and neck squamous cell carcinoma.
Need a specific report? 1000+ reports available
Buy Reports